Transporters in drug-refractory epilepsy: clinical significance.
about
Intracellular and circulating neuronal antinuclear antibodies in human epilepsyWhat non-neuronal mechanisms should be studied to understand epileptic seizures?A multi-system approach assessing the interaction of anticonvulsants with P-gpNanomaterial-mediated CNS delivery of diagnostic and therapeutic agents.Polymorphism of ABCB1/MDR1 C3435T in children and adolescents with partial epilepsy is due to different criteria for drug resistance - preliminary results.Cellular localization and functional significance of CYP3A4 in the human epileptic brain.Sertraline-induced potentiation of the CYP3A4-dependent neurotoxicity of carbamazepine: an in vitro study.Monocarboxylate transporter 1 is deficient on microvessels in the human epileptogenic hippocampus.Altered expression of brain monocarboxylate transporter 1 in models of temporal lobe epilepsyBlood-brain barrier dysfunction in epileptogenesis of the temporal lobeCYP3A5*3 and C3435T MDR1 polymorphisms in prognostication of drug-resistant epilepsy in children and adolescentsExpression and functional relevance of UGT1A4 in a cohort of human drug-resistant epileptic brains.A pro-convulsive carbamazepine metabolite: quinolinic acid in drug resistant epileptic human brain.Overexpression of pregnane X and glucocorticoid receptors and the regulation of cytochrome P450 in human epileptic brain endothelial cells.Blood-brain barrier P450 enzymes and multidrug transporters in drug resistance: a synergistic role in neurological diseases.Are you in or out? Leukocyte, ion, and neurotransmitter permeability across the epileptic blood-brain barrier.Multidrug resistance proteins expression in glioma patients with epilepsy.
P2860
Q22252354-5326F36F-3125-444E-84DE-E254881D61F4Q26853726-64D21C1D-C9A8-43B9-963B-A766780AA32BQ28533527-15FE9F5F-496D-4F9A-86AB-2B520E6A0FD5Q34104503-036142B7-C1D2-42D3-BC84-3908832DCF3AQ34237989-F5FEB8F7-F516-4D43-8FE4-EBFA146146E7Q34669448-8019E847-37FE-4232-B00A-25B32190FBAAQ35551134-AC4496D9-BBF4-42F7-B4B0-2293DC1FB499Q35901040-4C811BCD-C4F1-4A6E-881E-215ADF090BF5Q35955691-A5AFEA3F-0553-40C2-923E-470FBF03CACCQ36168832-1ABBCD7F-6D4A-4F12-A8F7-7DC066779BA7Q37104987-266C709D-CCA7-4810-B51F-B0A47F300E46Q37249054-815B27A7-14A8-4E74-9873-5BBF4C6FAED2Q37727201-741D18E1-C6EA-4CDF-92E0-AF9F601E3D56Q37746377-73F3F8FE-D9FD-4666-965E-5ACC705400F4Q37875183-C012BCC9-7A28-4DE1-9FC5-97DA445D6713Q38011831-68D96773-D7D4-4C2E-A828-F84CE6A65AE9Q47340679-045B620E-4AAF-48D9-A68F-D50BD170D28F
P2860
Transporters in drug-refractory epilepsy: clinical significance.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Transporters in drug-refractory epilepsy: clinical significance.
@en
Transporters in drug-refractory epilepsy: clinical significance.
@nl
type
label
Transporters in drug-refractory epilepsy: clinical significance.
@en
Transporters in drug-refractory epilepsy: clinical significance.
@nl
prefLabel
Transporters in drug-refractory epilepsy: clinical significance.
@en
Transporters in drug-refractory epilepsy: clinical significance.
@nl
P2860
P50
P356
P1476
Transporters in drug-refractory epilepsy: clinical significance
@en
P2093
J Gonzalez-Martinez
M-T Nguyen
P2860
P356
10.1038/CLPT.2009.225
P407
P577
2010-01-01T00:00:00Z